세쿠키누맙 (Korean Wikipedia)

Analysis of information sources in references of the Wikipedia article "세쿠키누맙" in Korean language version.

refsWebsite

Global rank Korean rank

7nih.gov

4^th place

6doi.org

2^nd place

3^rd place

2tga.gov.au

3,984^th place

1,245^th place

2semanticscholar.org

11^th place

310^th place

2fda.gov

447^th place

433^rd place

1medicines.org.uk

3,823^rd place

2,321^st place

1europa.eu

68^th place

145^th place

1mfds.go.kr

low place

1,240^th place

1genengnews.com

low place

1google.com

163^rd place

63^rd place

1web.archive.org

1^st place

1novartis.com

low place

1mdmag.com

low place

doi.org

dx.doi.org

Patel NU, Vera NC, Shealy ER, Wetzel M, Feldman SR (December 2017). “A Review of the Use of Secukinumab for Psoriatic Arthritis”. 《Rheumatology and Therapy》 4 (2): 233–246. doi:10.1007/s40744-017-0076-0. PMC 5696288. PMID 28849401.
Marwaha AK, Leung NJ, McMurchy AN, Levings MK (2012). “TH17 Cells in Autoimmunity and Immunodeficiency: Protective or Pathogenic?”. 《Frontiers in Immunology》 3: 129. doi:10.3389/fimmu.2012.00129. PMC 3366440. PMID 22675324.
Lubrano E, Perrotta FM (2016). “Secukinumab for ankylosing spondylitis and psoriatic arthritis”. 《Therapeutics and Clinical Risk Management》 12: 1587–1592. doi:10.2147/TCRM.S100091. PMC 5085310. PMID 27799780.
Shirley M, Scott LJ (July 2016). “Secukinumab: A Review in Psoriatic Arthritis”. 《Drugs》 76 (11): 1135–1145. doi:10.1007/s40265-016-0602-3. PMID 27299434. S2CID 24638664.
Nelson AL, Dhimolea E, Reichert JM (October 2010). “Development trends for human monoclonal antibody therapeutics”. 《Nature Reviews. Drug Discovery》 9 (10): 767–774. doi:10.1038/nrd3229. PMID 20811384. S2CID 594719.
Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, 외. (October 2010). “Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis”. 《Science Translational Medicine》 2 (52): 52ra72. doi:10.1126/scitranslmed.3001107. PMID 20926833.

europa.eu

ema.europa.eu

“Cosentyx EPAR”. 《European Medicines Agency (EMA)》. 2020년 5월 7일에 확인함. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

fda.gov

accessdata.fda.gov

“Drug Approval Package: Cosentyx (secukinumab) NDA #125504”. 《U.S. Food and Drug Administration (FDA)》. 1999년 12월 24일. 2020년 5월 7일에 확인함.

fda.gov

“FDA approves new psoriasis drug Cosentyx” (보도 자료). U.S. Food and Drug Administration (FDA). 2015년 1월 21일. 2015년 1월 22일에 원본 문서에서 보존된 문서. 2015년 1월 21일에 확인함.

genengnews.com

“Novartis Snags Remaining 23% Stake in Alcon with $12.9B Cash and Share Deal”. 《Genetic Engineering News》. 2010년 12월 15일.

google.com

Di Padova FE, Gram H, Hofstetter H, Jeschke M, Rondeau JM, Van Den Berg W (2010). “US 7807155: IL-17 antagonistic antibodies”.

mdmag.com

“FDA Approves Label Update for Secukinumab”. 《MD Magazine》. 2018년 6월 27일에 확인함.

medicines.org.uk

“Cosentyx 150mg and 300mg solution for injection in pre-filled syringe and pre-filled pen - Summary of Product Characteristics (SmPC)”. 《(emc)》. 2022년 6월 6일. 2022년 11월 9일에 확인함.

mfds.go.kr

nedrug.mfds.go.kr

“코센틱스센소레디펜(세쿠키누맙,유전자재조합)”. 《의약품통합정보시스템》. 2023년 4월 11일에 확인함.

nih.gov

ncbi.nlm.nih.gov

Patel NU, Vera NC, Shealy ER, Wetzel M, Feldman SR (December 2017). “A Review of the Use of Secukinumab for Psoriatic Arthritis”. 《Rheumatology and Therapy》 4 (2): 233–246. doi:10.1007/s40744-017-0076-0. PMC 5696288. PMID 28849401.
Marwaha AK, Leung NJ, McMurchy AN, Levings MK (2012). “TH17 Cells in Autoimmunity and Immunodeficiency: Protective or Pathogenic?”. 《Frontiers in Immunology》 3: 129. doi:10.3389/fimmu.2012.00129. PMC 3366440. PMID 22675324.
Lubrano E, Perrotta FM (2016). “Secukinumab for ankylosing spondylitis and psoriatic arthritis”. 《Therapeutics and Clinical Risk Management》 12: 1587–1592. doi:10.2147/TCRM.S100091. PMC 5085310. PMID 27799780.
Shirley M, Scott LJ (July 2016). “Secukinumab: A Review in Psoriatic Arthritis”. 《Drugs》 76 (11): 1135–1145. doi:10.1007/s40265-016-0602-3. PMID 27299434. S2CID 24638664.
Nelson AL, Dhimolea E, Reichert JM (October 2010). “Development trends for human monoclonal antibody therapeutics”. 《Nature Reviews. Drug Discovery》 9 (10): 767–774. doi:10.1038/nrd3229. PMID 20811384. S2CID 594719.
Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, 외. (October 2010). “Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis”. 《Science Translational Medicine》 2 (52): 52ra72. doi:10.1126/scitranslmed.3001107. PMID 20926833.

dailymed.nlm.nih.gov

“Cosentyx- secukinumab injection”. 《DailyMed》. 2022년 11월 4일. 2022년 11월 9일에 확인함.

novartis.com

“Novartis receives two new FDA approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis in the US” (보도 자료). Novartis. 2016년 1월 15일.

semanticscholar.org

api.semanticscholar.org

Shirley M, Scott LJ (July 2016). “Secukinumab: A Review in Psoriatic Arthritis”. 《Drugs》 76 (11): 1135–1145. doi:10.1007/s40265-016-0602-3. PMID 27299434. S2CID 24638664.
Nelson AL, Dhimolea E, Reichert JM (October 2010). “Development trends for human monoclonal antibody therapeutics”. 《Nature Reviews. Drug Discovery》 9 (10): 767–774. doi:10.1038/nrd3229. PMID 20811384. S2CID 594719.

tga.gov.au

“Cosentyx (Novartis Pharmaceuticals Australia Pty Ltd)”. 《Therapeutic Goods Administration (TGA)》. 2022년 10월 7일. 2023년 4월 9일에 확인함.
“Prescription medicines: registration of new chemical entities in Australia, 2015”. 《Therapeutic Goods Administration (TGA)》. 2022년 6월 21일. 2023년 4월 10일에 확인함.

web.archive.org

“FDA approves new psoriasis drug Cosentyx” (보도 자료). U.S. Food and Drug Administration (FDA). 2015년 1월 21일. 2015년 1월 22일에 원본 문서에서 보존된 문서. 2015년 1월 21일에 확인함.